Cardiovascular Safety of β2-Adrenoceptor Agonist Use in Patients with Obstructive Airway Disease
- First Online:
- Cite this article as:
- Salpeter, S.R. Drugs Aging (2004) 21: 405. doi:10.2165/00002512-200421060-00005
- 107 Downloads
β2-Adrenoceptor agonists have been used as bronchodilators in the management of asthma and chronic obstructive pulmonary disease (COPD); however, there is evidence suggesting that β2-adrenoceptor agonist use may increase morbidity and mortality.
A systematic review of case-control studies and randomised controlled trials was performed to evaluate the cardiovascular safety of β2-adrenoceptor agonist use in patients with obstructive airway disease, defined as asthma or COPD.
Case-control studies have shown that β2-adrenoceptor agonist use is associated with an increased risk of myocardial infarction, congestive heart failure, cardiac arrest and sudden cardiac death. The degree of risk appears to be dose-dependent, and may be highest for new users and those with concomitant cardiac conditions. Pooled data from randomised placebo-controlled trials indicate that β2-adrenoceptor agonist use increases the risk of adverse cardiovascular events by more than 2-fold compared with placebo, thus providing evidence that the association seen in case-control studies is a causal one. Single doses of β2-adrenoceptor agonists significantly increase heart rate and decrease potassium concentrations compared with placebo.
Initiation of β2-adrenoceptor agonist treatment increases heart rate and decreases potassium concentrations, while continued use may increase the risk of adverse cardiovascular events. It could be through these effects of β-adrenergic stimulation that β2-adrenoceptor agonists may induce ischaemia, congestive heart failure, arrhythmias and sudden cardiac death. In addition to increasing adverse cardiovascular events, β2-adrenoceptor agonist use may induce respiratory tolerance and increase the risk of asthma attacks. It is not clear whether β2-adrenoceptor agonists should be used regularly in the treatment of obstructive airway disease, with or without concomitant cardiovascular disease.